Concordance of Anyplex™ II HPV HR assays with reference HPV assays in cervical cancer screening: Systematic review
Abstract
Introduction Genital infection with certain types of human papillomaviruses (HPVs) is a major cause of premalignant dysplasia and cervical cancer globally. Identification of 14 high-risk human papillomaviruses (HR-HPV) is immensely important in elucidating molecular epidemiology, patient monitoring, and evidence-based treatment. HPVs testing has become an essential part of current clinical practice in the management of cervical cancer and precancerous lesions. Thus, HPV assays are increasingly used for primary cervical screening and HPV genotyping, for monitoring vaccination-effect and determining changes in the epidemiology of viral genotypes across the globe. Testing for high-risk HPV is more effective in primary cervical cancer screening than in the cytological examination of a Pap smear. Separate genotyping may be useful for triage in both HPV-based and cytology-based screening. It should be used only for clinically validated tests. Aims To evaluate the concordance of Anyplex™ II HPV HR with other HPV assays in cervical cancer screening. Methods Validation studies of Anyplex™ II HPV HR assay from PubMed, google scholar, google database and Scopus were used to search articles. Articles published in English from 2013 onwards were systematically searched using keywords. Besides, other databases like Google Scholar and the Google database were searched manually for grey literature. The last search was done in December 2020. Then study eligibility, extracted data, and assessed…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Previous studies of these two assays using the non-inferiority test have validated their clinical performance for cervical cancer screening.
“However, previous studies of these two assays using the non-inferiority test have validated their clinical performance for cervical cancer screening [13, 37].”
From Comparison of Seegene Anyplex II HPV28 assay with BD Onclarity HPV assay for human papillomavirus genotyping (2022) · cites this paper as [37]
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042 · see citing works
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J., Bossuyt, P., Boutron, I., Hoffmann, T., mulrow, C., Shamseer, L., Tetzlaff, J., Akl, E., Brennan, S. E., et al. (2020) · doi:10.31222/osf.io/v7gm2_v1 · Cited by 8,090 · see citing works
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2021.03.001 · Cited by 4,265 · see citing works
Meijer, C. J. L. M., Berkhof, J., Castle, P. E., Hesselink, A. T., Franco, E. L., Ronco, G., Arbyn, M., Bosch, F. X., Cuzick, J., Dillner, J., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24010 · Cited by 692 · see citing works
Jacobs, M. V., Snijders, P. J. F., van den Brule, A. J. C., Helmerhorst, T. J. M., Meijer, C. J. L. M., & Walboomers, J. M. M. (1997) · Journal of Clinical Microbiology · doi:10.1128/jcm.35.3.791-795.1997 · Cited by 568 · see citing works
Comparing the performance of six human papillomavirus tests in a screening population
Cuzick, J., Cadman, L., Mesher, D., Austin, J., Ashdown-Barr, L., Ho, L., Terry, G., Liddle, S., Wright, C., Lyons, D., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.22 · Cited by 211 · see citing works
Clinical Validation of the cobas 4800 HPV Test for Cervical Screening Purposes
Heideman, D. A. M., Hesselink, A. T., Berkhof, J. H., van Kemenade, F. J., Melchers, W. J. G., Daalmeijer, N. F., Verkuijten, M. C. G. T., Meijer, C. J. L. M., & Snijders, P. J. F. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.05552-11 · Cited by 201 · see citing works
Commercially available molecular tests for human papillomaviruses: a global overview
Poljak, M., Oštrbenk, A., Domjanič, G. G., Xu, L., & Arbyn, M. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.03.033 · Cited by 136 · see citing works
Hesselink, A. T., Sahli, R., Berkhof, J., Snijders, P. J. F., van der Salm, M. L., Agard, D., Bleeker, M. C. G., & Heideman, D. A. M. (2016) · Journal of Clinical Virology · doi:10.1016/j.jcv.2016.01.009 · Cited by 61 · see citing works
Kwon, M.-J., Roh, K. H., Park, H., & Woo, H.-Y. (2014) · Journal of Clinical Virology · doi:10.1016/j.jcv.2014.01.015 · Cited by 55 · see citing works
Oštrbenk, A., Xu, L., Arbyn, M., & Poljak, M. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.01176-18 · Cited by 34 · see citing works
Clinical Validation of Anyplex II HPV HR Detection Test for Cervical Cancer Screening in Korea
Jung, S., Lee, B., Lee, K. N., Kim, Y., & Oh, E.-J. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2015-0117-oa · Cited by 33 · see citing works
Community-based self-collected human papillomavirus screening in rural Zimbabwe
Fitzpatrick, M. B., El‐Khatib, Z., Katzenstein, D. A., Pinsky, B. A., Chirenje, Z. M., & McCarty, K. (2019) · BMC Public Health · doi:10.1186/s12889-019-6810-5 · Cited by 29 · see citing works
Cornall, A. M., Poljak, M., Garland, S. M., Phillips, S., Tan, J. H., Machalek, D. A., Quinn, M. A., & Tabrizi, S. N. (2017) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-016-2831-5 · Cited by 22 · see citing works
Lee, D.-H., Hwang, N. R., Lim, M. C., Yoo, C. W., Joo, J., Kim, J., Park, S., & Hwang, S. (2015) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563215614036 · Cited by 22 · see citing works
Comparison of the Cobas 4800 HPV Test and the Seeplex HPV4A ACE with the Hybrid Capture 2 Test
Ki, E. Y., Kim, H., Choi, Y.-J., Park, J. S., Kang, C. S., & Lee, A. (2013) · International Journal of Medical Sciences · doi:10.7150/ijms.5460 · Cited by 14 · see citing works
Jung, H. Y., Han, H. S., Kim, H. B., Oh, S. Y., Lee, S., & Kim, W. Y. (2016) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2015.10.21 · Cited by 5 · see citing works
Prevalence of Human Papillomavirus in Laryngeal Squamous Cell Carcinoma in Azerbaijan Population
Aliyev, A. J., Melikova, L. A., Bagirova, E. E., Akbarov, K., Aliyeva, A. M., & Quliyev, N. A. (2018) · Head and Neck Cancer Research · doi:10.21767/2572-2107.100024 · Cited by 3 · see citing works
Flagged first, then by citations
1 of the 19 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Kim, M., Kim, J., Park, N. J.-Y., & Park, J. Y. (2022) · PLOS ONE · doi:10.1371/journal.pone.0267836 · Cited by 5 · see citing works
Virus del papiloma humano de alto riesgo y factores asociados en mujeres de Ecuador
Torres, Z. K. S., Cortez, J. M. H., Suárez, A. E. Z., & Heredia, F. R. C. (2022) · Revista Vive · doi:10.33996/revistavive.v5i15.178 · Cited by 4 · see citing works
Primary HPV Infection in Postmenopausal Women: A Cohort Study to Enable Risk-Stratified Management
Ye, J., & Wu, G. (2026) · International Journal of Women s Health · doi:10.2147/ijwh.s579297
Wang, H., Wu, L.-R., Guo, P.-F., Wang, L.-P., Li, H.-X., Wang, H., Wang, Y.-J., Shao, S. J., & Chen, S. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1850475
Eficacia y coste-efectividad de incluir el genotipado de VPH en el cribado de cáncer de cérvix
Gutiérrez-Pizarraya, A., Márquez, J. M. M., López, R. R., Blasco‐Amaro, J. A., Sánchez, F. J., García-Agua-Soler, N., González-Álvarez, M. L., & García-Ruiz, A. J. (2026) · doi:10.52766/nwdq7431
- Authors
- Biazin, H.
- Affiliations
- Addis Ababa University (ET)
- Corresponding author
- Biazin, Habtamu
- ORCID
- Biazin, Habtamu
- Venue
- Journal of Virological Methods
- Publisher
- Elsevier BV
- Published
- 2022-03
- Volume
- 301
- Pages
- 114435
- ISSN
- 0166-0934 (ISSN-L)
- OpenAlex
- W4200523197
- Cited by
- 5
- References
- 19
- Citations by year
- 2026: 3 · 2022: 2
- FWCI
- 0.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Journal of Virological Methods (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
- Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
- Keywords
- high-risk HPV genotyping, cervical cancer screening, CIN2+ detection, CIN3+ detection, sensitivity and specificity, HPV genotyping, risk of bias assessment, cervical intraepithelial neoplasia
- MeSH terms
- Uterine Cervical Neoplasms, Female, Humans, Sensitivity and Specificity, Reproducibility of Results, Papillomaviridae, Papillomavirus Infections, Early Detection of Cancer
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
